3 期试验显示 semaglutide 是一种肥胖药物，可显着减轻肥胖成人膝骨关节炎的疼痛。 Phase 3 trial reveals semaglutide, an obesity drug, significantly reduces knee osteoarthritis pain in obese adults.
发表在"新英格兰医学杂志"上的第三阶段试验发现, 治疗肥胖的药物西马格卢提德可显著缓解肥胖成年人的膝关节关节炎疼痛. A phase 3 trial published in The New England Journal of Medicine found that semaglutide, a drug for obesity, significantly alleviates knee osteoarthritis pain in obese adults. 68周以上,参加者平均体重减少13.7%,并报告说疼痛明显减少。 Over 68 weeks, participants lost an average of 13.7% of their body weight and reported a notable reduction in pain. 尽管结果表明 semaglutide 可能会改善身体机能并延迟手术，但目前在美国尚未批准用于骨关节炎治疗。需要进一步的研究。 Although results indicate semaglutide may improve physical function and delay surgery, it is not currently approved for osteoarthritis treatment in the U.S. Further research is needed.